ClinicalTrials.gg
RecruitingNCT05933720Updated Jul 6, 2023

Efficacy and Safety of the Regulatory Polypeptides in Patients With Peripheral Atherosclerosis.

An interventional study of Polypeptides and Femoral-popliteal bypass grafting with a synthetic graft above the knee in Peripheral Arterial Occlusive Disease, sponsored by Ryazan State Medical University. Recruiting at 1 site in Russian Federation. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-07-06.

Sponsored by Ryazan State Medical University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Apr 2023; still recruiting 3 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Peripheral Arterial Disease with a site in Russian Federation — 2 open to participants now, 2 under way, none of them phase 3. Peripheral Arterial Disease · Russian Federation.

Planned enrollment
15th of 19
120 · median 360
Started
2023
with 2 others
No phase
7 of 21
2 open now
Registered
20th of 21
by date
Lead sponsor
3 of 21
Ryazan State Medical University

Among the 21 studies in Peripheral Arterial Disease with a site in Russian Federation, this one is the 15th largest by planned enrollment of the 19 interventional ones that give a count, is one of 3 that started in 2023, is one of 7 with no phase, and was the 20th registered.

Peripheral Arterial Disease

1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.

Browse Peripheral Arterial Disease studies →

Open to participants now

2 of the 21 studies in Peripheral Arterial Disease with a site in Russian Federation are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Russian Federation have not opened yet or have stopped. Only those recruiting at a site in Russian Federation →

Who these studies take

Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Peripheral Arterial Disease with a site in Russian Federation, or all of them as a file.
02

Study summary

The study is aimed at assessing the role of the activity of markers of endothelial dysfunction (cytotoxic malonic aldehyde (MDA), angiotensin II, endothelial nitric oxide synthase (NO), endothelin-1, prostacyclin) in the systemic circulation in patients with lower extremity atherosclerotic arterial occlusive disease undergoing open reconstructive interventions.

Read the detailed description

The study will include 120 patients of similar age, gender, and ethnicity, they will be divided into four groups: Group I: 30 patients with lower extremity atherosclerotic arterial occlusive disease, stage IIA-IIB of the disease according to the Fontaine-Pokrovsky classification, receiving conservative therapy; Group II: 30 patients with lower extremity atherosclerotic arterial occlusive disease, stage IIA-IIB of the disease according to the Fontaine-Pokrovsky classification, receiving conservative therapy, including the drug based on vascular polypeptides Slavinorm®; Group III: 30 patients with lower extremity atherosclerotic arterial occlusive disease, stageIII-IV of the disease according to the Fontaine-Pokrovsky classification, receiving conservative therapy in combination with surgical methods of treatment (femoral-popliteal bypass grafting with a synthetic graft above the knee); Group IV: 30 patients with lower extremity atherosclerotic arterial occlusive disease, stage III-IV of the disease according to the Fontaine-Pokrovsky classification, receiving conservative therapy, including the drug based on vascular polypeptides Slavinorm®, in combination with surgical methods of treatment (femoral-popliteal bypass grafting with a synthetic graft above the knee).

03

Conditions studied

  • Peripheral Arterial Occlusive Disease

Keywords

  • Peripheral Arterial Disease
  • bypass grafting
  • polypeptides
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

men or women over 18 years of age with lower extremity atherosclerotic arterial occlusive disease, confirmed with instrumental work-up methods (ultrasonography or angiography).

Exclusion criteria

Exclusion Criteria:

men or women under 18 years of age; history of anaphylaxis; to any of the components that make up the drug Slavinorm®, and proteins of animal origin; absolute and relative to the treadmill test; failure to walk at a minimum speed of 3.2 km/h (2 mph) at a minimum treadmill angle for at least 2 minutes during the stress test during the screening phase; depression of the ST segment more than 1 mm in one or more standard leads on the ; peripheral artery disease not associated with atherosclerosis; patients who underwent reconstructive surgery or invasive interventions on the arteries of the lower extremities in history without a clinic of intermittent claudication; angina pectoris III-IV functional class (FC) according to the CCS classification; >35 kg/m2; acute or chronic renal ( less than 30 ml / min) and / or liver failure [ (AST), alanine aminotransferase (ALT) > 3 times the ]; chronic heart failure III-IV FC according to ; acute coronary syndrome within 6 months. before the start of the screening period; any condition or comorbidity that, in the opinion of the Investigator, would preclude the patient from participating in the study.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Active comparator
    Patients who undergo routine conservative treatment

    The patients who undergo routine conservative treatment for peripheral atherosclerotic occlusive disease as per clinical guidelines

    Other: Routine conservative treatment

  • Experimental
    Patients who undergo treatment with polypeptides

    The patients who undergo treatment with a complex of polypeptides isolated from the vessels of cattle is administered in / m, adults 1 vial (5 mg) 1 time / day 2 times a week. The course of treatment is 10 injections.

    Drug: Polypeptides

  • Active comparator
    Patients who undergo femoral-popliteal bypass with a synthetic graft above the knee

    Patients who undergo the surgical method of treatment i.e. femoral-popliteal bypass grafting with a synthetic graft above the knee and routine conservative treatment as per clinical guidelines

    Device: Femoral-popliteal bypass grafting with a synthetic graft above the knee · Other: Routine conservative treatment

  • Experimental
    Patients who undergo femoral-popliteal bypass grafting and treatment with polypeptides

    Patients who undergo the surgical method of treatment i.e. femoral-popliteal bypass grafting with a synthetic graft above the knee with following treatment with a complex of polypeptides isolated from the vessels of cattle is administered in / m, adults 1 vial (5 mg) 1 time / day 2 times a week. The course of treatment is 10 injections.

    Drug: Polypeptides · Device: Femoral-popliteal bypass grafting with a synthetic graft above the knee

Interventions

  • DrugPeptidesStudies of PeptidesPeptides pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The patients will undergo treatment with a drug based on vascular polypeptides Slavinorm®, a derivative from cattle vessels, registered in Russia for the treatment of patients with peripheral atherosclerotic occlusive disease.

    Also known as: vascular polypeptides Slavinorm®, a derivative from cattle vessels

  • DeviceFemoral-popliteal bypass grafting with a synthetic graft above the knee

    The patients with undergo an arterial revascularization - Femoral-popliteal bypass grafting with a synthetic graft above the knee

  • OtherRoutine conservative treatment

    The patients will undergo routine conservative treatment as per clinical guidelines (acetylsalicylic acid 100mg daily, atorvastatin 20mg daily)

06

What researchers measure

Primary outcomes

  1. Lower artery or bypass graft thrombosis

    The rate of the Lower artery or bypass graft thrombosis

    Time frame: 1 year

  2. disease progression

    The rate of the disease progression

    Time frame: 1 year

  3. restenosis

    Restenosis rate

    Time frame: 1 year

Secondary outcomes

  1. limb loss

    Limb loss rate

    Time frame: 1 year

  2. changes in pain-free walking distance

    Changes in the parameter of pain-free walking distance (in meters)

    Time frame: 1 year

  3. changes in ankle-brachial index

    Changes in the parameter of ankle-brachial index measured at rest

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
  • RyazanSMU
    Ryazan, Russian Federation
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Jun 2026, 38 months after the start.

Of 261 non-industry interventional studies with no phase under Peripheral Arterial Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 64. This study's planned 38 months is above that.

Counting every sponsor, half of 386 studies reached it within 31 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2023
First posted
Jul 6, 2023
StartActual
Apr 1, 2023
Primary completionEst.
Jun 1, 2026
CompletionEst.
Sep 1, 2026
Last update
Jul 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05933720
Lead sponsor
Ryazan State Medical University
Responsible party
Lyasheva Anastasia Vladimirovna (Resident cardiovascular surgeon in the Department of Cardiovascular, Endovascular Surgery and Diagnostic Radiology, Ryazan State Medical University) — Principal investigator
First posted
Jul 6, 2023
Start date
Apr 1, 2023
Primary completion
Jun 1, 2026 (estimated)
Completion
Sep 1, 2026 (estimated)
Last update
Jul 6, 2023

Study contacts

Igor Aleksadrovich Suchkov
Contact
suchkov_med@mail.ru
8-903-836-24-17
Igor Suchkov
study chair · Ryazan State Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Peptides

Start the discussion